

## A REVIEW ON COMMON BILE DUCT CANCER AND ITS MANAGEMENT IN INDIA



Dr. Ram Garg<sup>1\*</sup>, Vijeta Sharma<sup>2</sup>

<sup>1</sup>Professor, <sup>2</sup>Research Scholar, Department of Pharmacology, Arya Collage of Pharmacy, Jaipur, Rajasthan, India.

**Corresponding Author\*:** Dr. Ram Garg, Department of Pharmacology, Arya Collage of Pharmacy, Jaipur, Rajasthan, India.

**Email ID:** [ramgarg20@gmail.com](mailto:ramgarg20@gmail.com)

**DOI:** <https://doi.org/10.59551/IJHMP/25832069/2025.6.1.30>

**COPYRIGHT@ 2025, IJHMP** | This work is licensed under a [Creative Commons Attribution 4.0 International Licence](https://creativecommons.org/licenses/by/4.0/)

Received: 15 Jan, 2025, Decision for Acceptance: 18 Feb, 2025

### Abstract

Common bile duct cancer, also known as cholangiocarcinoma, which is caused by epithelial cells lining the bile ducts is rare but dangerously dangerous. Its incidence is very low compared to other stomach cancers in India but its management has important clinical and systemic challenges, where its epidemiology, risk factors, includes clinical presentation, diagnostic challenges, management strategies, socioeconomic impact, culturally theory, future directions, emerging trends, palliative care, survival, and rehabilitation, patient education, and support groups.

**Keywords:** Common bile duct cancer, Cholangiocarcinoma, Epidemiology, Risk factors, Clinical presentation, Diagnosis, Management, Challenges, Future Directions, Palliative Care, Survivorship, Rehabilitation, Patient Education, Support Groups.

### 1. Introduction

Common bile duct cancer or cholangiocarcinoma is a rare but aggressive malignancy of epithelial cells lining the bile ducts. Its incidence is relatively low compared to other gastric cancers in India, but it is clinical and systemic of significant implementation challenges. Strategies, socioeconomic impact, cultural considerations, future Guidelines, emerging trends, palliative care, restorative life, patient education, and support group management are presented combined for Common bile duct cancer in India.

### 2. Epidemiology

Reliable information on the incidence and prevalence of bile duct cancer in India is limited, mainly due to misinformation and lack of centralized cancer registries but studies show an increase, possibly with factors such as liver association between chronic intestinal disease, viral hepatitis and environmental toxicity.

### 3. Risk Factors

Many risk factors contribute to bile duct cancer in India, including chronic liver diseases like primary sclerosing cholangitis, hepatitis B-C infection other risk factors include choledochal cysts, parasitic infections (e.g. liver fluke), carcinogens like tobacco aflatoxin, obesity, diet and there are s Understanding these risks is critical for targeted prevention efforts and early detection efforts.

#### **4. Clinical Presentation**

Prostate cancer often presents with nonspecific symptoms, leading to delayed diagnosis and severe disease at presentation. The most common clinical manifestations are jaundice, abdominal pain, weight loss, pain, and symptoms of urinary retention. However, these symptoms can overlap with benign biliary conditions, making an accurate diagnosis difficult.

#### **4. Diagnostic Challenges**

Bile duct cancer diagnosis in India is hampered by unavailability of advanced medicine like Magnetic Resonance Imaging (MRI), Endoscopic Retrograde Cholangiopancreatography (ERCP), tissue biopsy facilities, especially in rural and underserved areas and depends on factors many of these. Strengthening diagnostic tools and knowledge base is essential for timely and accurate diagnosis.

#### **5. Management Strategies**

Management of bile duct cancer in India requires a multidisciplinary approach involving surgeons, medical oncologists, radiation oncologists and veterinary teams Surgical excision is the cornerstone of treatment of the local disease, however the likelihood and range is generally limited to what allergy symptoms and patient factors can provide for platinum and other dietary supplements . In severe or mild cases, palliative care aimed at relieving symptoms and maintaining quality of life is essential.

#### **6. Challenges in Management**

A variety of challenges hinder the successful management of bile duct cancer in India, including limited access to specialized cancer centers, financial barriers and cultural beliefs about cancer care that are exacerbated by presentation later, due to advanced disease at diagnosis and lack of a standardized treatment plan. Moreover, the heterogeneity of access to healthcare and infrastructure increases the burden of disease.

#### **7. Socioeconomic Impact and Cultural Considerations**

Bile duct cancer not only affects the health of individuals but also places a huge social and economic burden on patients and their families in India. Increased medical costs, loss of productivity, and psychosocial distress contribute to the financial and emotional stress of affected individuals. Furthermore, cultural beliefs and stigmas associated with cancer often influence health care-seeking behaviors, delaying diagnosis and initiation of treatment.

#### **8. Future Directions and Emerging Trends**

Addressing the bile duct cancer burden in India requires a multi-pronged approach including public health policy, policy initiatives and research improvements Future efforts should focus on providing cancer awareness and research agenda improvement, health care enhancement and access to facilities for diagnosis and treatment, of new diagnostic biomarkers, of targeted therapies , research on personalized medicine and strategies hold promise to improve outcomes and reduce morbidity and mortality associated with bile duct cancer.

#### **9. Palliative Care and Quality of Life**

Because more information is diagnosed at an advanced time point, palliative care plays an important role in improving quality of life in patients with advanced bile duct cancer Symptom management, psychological support, and end-of-life care are essential components of palliative care interventions aimed at maximizing comfort and dignity for patients and their families.

#### **10. Survivorship and Rehabilitation**

For patients who undergo surgical resection or receive curative treatment, survivorship rehabilitation programs are essential to optimize long-term outcomes These programs draw attention

emphasize physical rehabilitation, nutritional support, psychosocial counseling, and relapse monitoring, aimed at helping survivors return to work and adjust to life time after cancer treatment.

### 11. Patient Education and Support Groups

Empowering patients and caregivers through education and support groups can help prevent anxiety, enhance coping skills, and improve treatment adherence Establishment of a patient education program with an eye toward promoting self-care, symptom management, and lifestyle change Strength and resilience in individuals affected by bile duct cancer can regulate emotions.

### 12. Conclusion

The common cancer of the bile duct represents a major clinical challenge in India, characterized by late diagnosis, limited resources, and complex management considerations and those complications addressing this issue requires a concerted effort by health professionals, policy makers and communities to improve early detection, quality of care and patient outcomes . By implementing comprehensive strategies including disease prevention, early detection and evidence-based treatment, we can reduce the impact of bile duct cancer and improve the lives of affected individuals on the whole of India.

**13. Conflict of Interest:** None

### 14. References

1. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillmoen KD, Yeo CJ, Cameron JL. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. *Ann Surg.* 1996; 224:463–73; discussion 473-5.
2. Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Wasan H British Society of Gastroenterology. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. *Gut.* 2012; 61:1657–1669.
3. Massarweh NN, El-Serag HB. Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. *Cancer Control.* 2017; 24:1073274817729245.
4. Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. *Nat Rev Gastroenterol Hepatol.* 2011; 8:512–522.
5. Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RI, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJ, Alvaro D. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) *Nat Rev Gastroenterol Hepatol.* 2016; 13:261–280.
6. Alvaro D, Bragazzi MC, Benedetti A, Fabris L, Fava G, Invernizzi P, Marzioni M, Nuzzo G, Strazzabosco M, Stroffolini T AISF “Cholangiocarcinoma” committee. Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the “Cholangiocarcinoma” committee of the Italian Association for the Study of Liver disease. *Dig Liver Dis.* 2011; 43:60–65.
7. De Rose AM, Cucchetti A, Clemente G, Ardito F, Giovannini I, Ercolani G, Giuliante F, Pinna AD, Nuzzo G. Prognostic significance of tumor doubling time in mass-forming type cholangiocarcinoma. *J Gastrointest Surg.* 2013; 17:739–747.
8. Rimola J, Forner A, Reig M, Vilana R, de Lope CR, Ayuso C, Bruix J. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. *Hepatology.* 2009; 50:791–798.
9. Iavarone M, Piscaglia F, Vavassori S, Galassi M, Sangiovanni A, Venerandi L, Forzenigo LV, Golfieri R, Bolondi L, Colombo M. Contrast

- enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis. *J Hepatol*. 2013; 58:1188–1193.
10. Rullier A, Le Bail B, Fawaz R, Blanc JF, Saric J, Bioulac-Sage P. Cytokeratin 7 and 20 expressions in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis. *Am J Surg Pathol*. 2000; 24:870–876.
  11. Lau SK, Prakash S, Geller SA, Alsabeh R. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. *Hum Pathol*. 2002; 33:1175–1181.
  12. Liao JY, Tsai JH, Yuan RH, Chang CN, Lee HJ, Jeng YM. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features. *Mod Pathol*. 2014; 27:1163–1173.
  13. Nakanuma Y, Sato Y, Harada K, Sasaki M, Xu J, Ikeda H. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. *World J Hepatol*. 2010; 2:419–427.
  14. Komuta M, Spee B, Vander Borght S, De Vos R, Verslype C, Aerts R, Yano H, Suzuki T, Matsuda M, Fujii H, Desmet VJ, Kojiro M, Roskams T. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. *Hepatology*. 2008; 47:1544–1556.
  15. Komuta M, Govaere O, Vandecaveye V, Akiba J, Van Steenberghe W, Verslype C, Laleman W, Pirenne J, Aerts R, Yano H, Nevens F, Topal B, Roskams T. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. *Hepatology*. 2012; 55:1876–1888.
  16. Romagnuolo J, Bardou M, Rahme E, Joseph L, Reinhold C, Barkun AN. Magnetic resonance cholangiopancreatography: a meta-analysis of test performance in suspected biliary disease. *Ann Intern Med*. 2003; 139:547–557.
  17. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ American Association for the Study of Liver Diseases. Diagnosis and management of primary sclerosing cholangitis. *Hepatology*. 2010; 51:660–678.
  18. Mansour JC, Aloia TA, Crane CH, Heimbach JK, Nagino M, Vauthey JN. Hilar cholangiocarcinoma: expert consensus statement. *HPB (Oxford)* 2015; 17:691–699.
  19. Abu-Wasel B, Keough V, Renfrew PD, Molinari M. Biliary stent therapy for dominant strictures in patients affected by primary sclerosing cholangitis. *Pathobiology*. 2013; 80:182–193.

Cite this article Garg R et al., A Review on Common Bile Duct Cancer and its Management In India. Indian Journal of Health Care, Medical & Pharmacy Practice. 2025;6(1):15-18.